Cargando…

A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration

BACKGROUND: Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryer, Emily J., Kallan, Michael J., Chiu, Ting‐Shan, Scheuba, Katharina M., Henry, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175772/
https://www.ncbi.nlm.nih.gov/pubmed/35847693
http://dx.doi.org/10.1002/jha2.18
_version_ 1784722521255313408
author Bryer, Emily J.
Kallan, Michael J.
Chiu, Ting‐Shan
Scheuba, Katharina M.
Henry, David H.
author_facet Bryer, Emily J.
Kallan, Michael J.
Chiu, Ting‐Shan
Scheuba, Katharina M.
Henry, David H.
author_sort Bryer, Emily J.
collection PubMed
description BACKGROUND: Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs. METHODS: A retrospective study analyzed 10,269 University of Pennsylvania Health System patients with malignancies of various type, stage, and histopathology who developed CIA between 2008 and 2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after adjusting for RBC and ESA intervention (all during the 90 days following CIA diagnosis). RESULTS: Among the 10,269 patients with CIA, 2,642 (25.7%) developed a VTE within the 90‐day period. VTE risk following RBC transfusion (HR = 1.37, 95% CI 1.24‐1.50, P < .001) was more than twice as common as VTE risk following ESA administration (HR = 0.53, 95% CI 0.40‐0.69, P < .001). CONCLUSION: While both RBC transfusion and ESA are independently associated with VTE, our data suggest a greater risk of VTE development with RBC transfusion as compared with ESA.
format Online
Article
Text
id pubmed-9175772
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91757722022-07-14 A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration Bryer, Emily J. Kallan, Michael J. Chiu, Ting‐Shan Scheuba, Katharina M. Henry, David H. EJHaem Sickle Cell, Thrombosis, and Haematology BACKGROUND: Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs. METHODS: A retrospective study analyzed 10,269 University of Pennsylvania Health System patients with malignancies of various type, stage, and histopathology who developed CIA between 2008 and 2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after adjusting for RBC and ESA intervention (all during the 90 days following CIA diagnosis). RESULTS: Among the 10,269 patients with CIA, 2,642 (25.7%) developed a VTE within the 90‐day period. VTE risk following RBC transfusion (HR = 1.37, 95% CI 1.24‐1.50, P < .001) was more than twice as common as VTE risk following ESA administration (HR = 0.53, 95% CI 0.40‐0.69, P < .001). CONCLUSION: While both RBC transfusion and ESA are independently associated with VTE, our data suggest a greater risk of VTE development with RBC transfusion as compared with ESA. John Wiley and Sons Inc. 2020-05-26 /pmc/articles/PMC9175772/ /pubmed/35847693 http://dx.doi.org/10.1002/jha2.18 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Sickle Cell, Thrombosis, and Haematology
Bryer, Emily J.
Kallan, Michael J.
Chiu, Ting‐Shan
Scheuba, Katharina M.
Henry, David H.
A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
title A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
title_full A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
title_fullStr A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
title_full_unstemmed A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
title_short A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
title_sort retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: red blood cell transfusion versus erythrocyte stimulating agent administration
topic Sickle Cell, Thrombosis, and Haematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175772/
https://www.ncbi.nlm.nih.gov/pubmed/35847693
http://dx.doi.org/10.1002/jha2.18
work_keys_str_mv AT bryeremilyj aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT kallanmichaelj aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT chiutingshan aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT scheubakatharinam aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT henrydavidh aretrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT bryeremilyj retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT kallanmichaelj retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT chiutingshan retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT scheubakatharinam retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration
AT henrydavidh retrospectiveanalysisofvenousthromboembolismtrendsinchemotherapyinducedanemiaredbloodcelltransfusionversuserythrocytestimulatingagentadministration